Latest news with #CancerDx
Yahoo
04-05-2025
- Business
- Yahoo
Idexx Laboratories price target raised to $460 from $420 at Stifel
Stifel raised the firm's price target on Idexx Laboratories (IDXX) to $460 from $420 and keeps a Hold rating on the shares. The firm says that the company's Q1 results were not surprising, but the stock's reaction was a bit stronger than expected. Stifel will continue to monitor the uptake of Cancer Dx and inVue, but for now the firm believes the near-term contribution is already reflected in estimates. Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on IDXX: Disclaimer & DisclosureReport an Issue Early notable gainers among liquid option names on May 1st Idexx Laboratories: Stable Performance and Growth Potential Amid Market Challenges Idexx Laboratories reports Q1 EPS $2.96, consensus $2.84 Idexx Laboratories raises 2025 EPS view 19c to $11.93-$12.43, consensus $11.99 Is IDXX a Buy, Before Earnings?
Yahoo
02-05-2025
- Business
- Yahoo
IDEXX Laboratories [NasdaqGS:IDXX] Raises 2025 Guidance and Reports Q1 Growth in Revenue and EPS
IDEXX Laboratories experienced a 13% price increase over the last month, spurred by robust first-quarter earnings results and an optimistic upward revision in corporate guidance. The company reported an increase in sales and net income compared to the previous year, projecting confidence for the remainder of 2025. These positive events coincided with a broader market uptick, including a strong U.S. jobs report and potential trade talk optimism, both bolstering the S&P 500's performance. While these market conditions supported IDEXX's rise, the company's own positive announcements likely added weight to its strong performance. We've discovered 1 warning sign for IDEXX Laboratories that you should be aware of before investing here. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. IDEXX Laboratories' recent 13% share price increase stems from strong first-quarter earnings and optimistic guidance revisions, positioning the company well for revenue and earnings growth in 2025. These developments align with their narrative of expanding international markets and enhancing software platforms. The investment in innovative diagnostic tools like inVue Dx and Cancer Dx appears to support these growth forecasts. Over the past five years, IDEXX's total shareholder return, accounting for both share price and dividends, rose 60.19%. This demonstrates a solid performance, though the company's 1-year return lagged behind the US Medical Equipment industry, which saw a 6.3% gain. The company's projected revenue growth of 7.3% per year, driven by increased international presence and strategic customer agreements, aligns with the recent earnings report results. However, challenges such as rising operating costs and unfavorable currency rates could impact these projections. The share price, currently at US$436.97, shows a discount compared to the consensus analyst price target of US$486.12, indicating potential room for growth if analysts' forecasts hold true. Examine IDEXX Laboratories' past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:IDXX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
